Michael J. Theodorakis

TL;DR: The coexistence of type 2 diabetes mellitus and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent and associated with a higher risk of HF hospitalization, all‐cause and cardiovascular (CV) mortality.

TL;DR: The Acarbose Cardiovascular Evaluation (ACE) trial was a randomized, double-blind, placebo-controlled, phase 4 trial, with patients recruited from 176 hospital outpatient clinics in China as discussed by the authors, where patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1), in blocks by site, by a centralised computer system to receive oral acarbose (50 mg three times a day) or matched placebo, which was added to standardised cardiovascular secondary prevention therapy.

TL;DR: GIP is unable to further amplify the insulinotropic and glucose-lowering effects of GLP-1 in type 2 diabetes, and the suppression of glucagon elicited by GLp-1 was antagonized by the addition of GIP.

TL;DR: AKI after stroke is a powerful and independent predictor of 10-yr mortality and new composite cardiovascular events.

TL;DR: Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.